Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib

Breast cancer is the most widespread malignancy in women worldwide. Nanostructured lipid carriers (NLCs) have proven effective in the treatment of cancer. NLCs loaded with imatinib (IMA) (NANIMA) were prepared and evaluated for their in vitro efficacy in MCF-7 breast cancer cells. The hot homogeniza...

Full description

Bibliographic Details
Main Authors: Hafiz A. Makeen, Syam Mohan, Mohamed Ahmed Al-Kasim, Muhammad Hadi Sultan, Ahmed A. Albarraq, Rayan A. Ahmed, Hassan A. Alhazmi, M. Intakhab Alam
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceutics
Subjects:
NLC
SLS
Online Access:https://www.mdpi.com/1999-4923/13/7/1086
id doaj-d4e5bd8655dd4e609e7a650c84d2fced
record_format Article
spelling doaj-d4e5bd8655dd4e609e7a650c84d2fced2021-07-23T14:00:52ZengMDPI AGPharmaceutics1999-49232021-07-01131086108610.3390/pharmaceutics13071086Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing ImatinibHafiz A. Makeen0Syam Mohan1Mohamed Ahmed Al-Kasim2Muhammad Hadi Sultan3Ahmed A. Albarraq4Rayan A. Ahmed5Hassan A. Alhazmi6M. Intakhab Alam7Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaSubstance Abuse and Toxicology Research Centre, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmacology, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmacology, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaSubstance Abuse and Toxicology Research Centre, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaBreast cancer is the most widespread malignancy in women worldwide. Nanostructured lipid carriers (NLCs) have proven effective in the treatment of cancer. NLCs loaded with imatinib (IMA) (NANIMA) were prepared and evaluated for their in vitro efficacy in MCF-7 breast cancer cells. The hot homogenization method was used for the preparation of NANIMAs. An aqueous solution of surfactants (hot) was mixed with a molten mixture of stearic acid and sesame oil (hot) under homogenization. The prepared NANIMAs were characterized and evaluated for size, polydispersity index, zeta potential, encapsulation efficiency, release studies, stability studies, and MTT assay (cytotoxicity studies). The optimized NANIMAs revealed a particle size of 104.63 ± 9.55 d.nm, PdI of 0.227 ± 0.06, and EE of 99.79 ± 0.03. All of the NANIMAs revealed slow and sustained release behavior. The surfactants used in the preparation of the NANIMAs exhibited their effects on particle size, zeta potential, encapsulation efficiency, stability studies, and release studies. The cytotoxicity studies unveiled an 8.75 times increase in cytotoxicity for the optimized NANIMAs (IC<sub>50</sub> = 6 µM) when compared to IMA alone (IC<sub>50</sub> = 52.5 µM) on MCF-7 breast cancer cells. In the future, NLCs containing IMA will possibly be employed to cure breast cancer. A small amount of IMA loaded into the NLCs will be better than IMA alone for the treatment of breast cancer. Moreover, patients will likely exhibit less adverse effects than in the case of IMA alone. Consequently, NANIMAs could prove to be useful for effective breast cancer treatment.https://www.mdpi.com/1999-4923/13/7/1086imatinibNLCTween 80SLSMTT assayrelease study
collection DOAJ
language English
format Article
sources DOAJ
author Hafiz A. Makeen
Syam Mohan
Mohamed Ahmed Al-Kasim
Muhammad Hadi Sultan
Ahmed A. Albarraq
Rayan A. Ahmed
Hassan A. Alhazmi
M. Intakhab Alam
spellingShingle Hafiz A. Makeen
Syam Mohan
Mohamed Ahmed Al-Kasim
Muhammad Hadi Sultan
Ahmed A. Albarraq
Rayan A. Ahmed
Hassan A. Alhazmi
M. Intakhab Alam
Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib
Pharmaceutics
imatinib
NLC
Tween 80
SLS
MTT assay
release study
author_facet Hafiz A. Makeen
Syam Mohan
Mohamed Ahmed Al-Kasim
Muhammad Hadi Sultan
Ahmed A. Albarraq
Rayan A. Ahmed
Hassan A. Alhazmi
M. Intakhab Alam
author_sort Hafiz A. Makeen
title Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib
title_short Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib
title_full Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib
title_fullStr Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib
title_full_unstemmed Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib
title_sort preparation, characterization, and anti-cancer activity of nanostructured lipid carriers containing imatinib
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2021-07-01
description Breast cancer is the most widespread malignancy in women worldwide. Nanostructured lipid carriers (NLCs) have proven effective in the treatment of cancer. NLCs loaded with imatinib (IMA) (NANIMA) were prepared and evaluated for their in vitro efficacy in MCF-7 breast cancer cells. The hot homogenization method was used for the preparation of NANIMAs. An aqueous solution of surfactants (hot) was mixed with a molten mixture of stearic acid and sesame oil (hot) under homogenization. The prepared NANIMAs were characterized and evaluated for size, polydispersity index, zeta potential, encapsulation efficiency, release studies, stability studies, and MTT assay (cytotoxicity studies). The optimized NANIMAs revealed a particle size of 104.63 ± 9.55 d.nm, PdI of 0.227 ± 0.06, and EE of 99.79 ± 0.03. All of the NANIMAs revealed slow and sustained release behavior. The surfactants used in the preparation of the NANIMAs exhibited their effects on particle size, zeta potential, encapsulation efficiency, stability studies, and release studies. The cytotoxicity studies unveiled an 8.75 times increase in cytotoxicity for the optimized NANIMAs (IC<sub>50</sub> = 6 µM) when compared to IMA alone (IC<sub>50</sub> = 52.5 µM) on MCF-7 breast cancer cells. In the future, NLCs containing IMA will possibly be employed to cure breast cancer. A small amount of IMA loaded into the NLCs will be better than IMA alone for the treatment of breast cancer. Moreover, patients will likely exhibit less adverse effects than in the case of IMA alone. Consequently, NANIMAs could prove to be useful for effective breast cancer treatment.
topic imatinib
NLC
Tween 80
SLS
MTT assay
release study
url https://www.mdpi.com/1999-4923/13/7/1086
work_keys_str_mv AT hafizamakeen preparationcharacterizationandanticanceractivityofnanostructuredlipidcarrierscontainingimatinib
AT syammohan preparationcharacterizationandanticanceractivityofnanostructuredlipidcarrierscontainingimatinib
AT mohamedahmedalkasim preparationcharacterizationandanticanceractivityofnanostructuredlipidcarrierscontainingimatinib
AT muhammadhadisultan preparationcharacterizationandanticanceractivityofnanostructuredlipidcarrierscontainingimatinib
AT ahmedaalbarraq preparationcharacterizationandanticanceractivityofnanostructuredlipidcarrierscontainingimatinib
AT rayanaahmed preparationcharacterizationandanticanceractivityofnanostructuredlipidcarrierscontainingimatinib
AT hassanaalhazmi preparationcharacterizationandanticanceractivityofnanostructuredlipidcarrierscontainingimatinib
AT mintakhabalam preparationcharacterizationandanticanceractivityofnanostructuredlipidcarrierscontainingimatinib
_version_ 1721286493832478720